ALLOPURINOL 300mg Tablet

Allopurinol 300 mg


Allopurinol Tablet 300 mg, each tablet contains : Allopurinol 300 mg.



Allopurinol with active ingredient Allopurinol available as tablet 100 mg and 300 mg.



  • Primary hyperuricemia : G
  • Secondary hyperuricemia : Prevents the sedimentation of uric acid and calcium oxalate, uric acid overproduction, such as in malignancy, polycythemia vera, cytostatic therapy.



Adult :

Initial dosage : 100 – 300 mg daily.

Maintenance dosage : 200 – 600 mg daily.

The maximum single dosage is 300 mg. If required it may be given in higher dosage, maximum 900 mg a day. The dosage should be adjusted by monitoring the levels of uric acid in serum/urine with appropriate interval time until the desired effect is achieved for ± 1 – 3 weeks, or :

  • Mild condition : 2 – 10 mg/kgBW daily or 100 – 200 mg daily.
  • Moderate condition : 300 – 600 mg daily.
  • Severe condition : 700 – 900 mg daily.

Children :

10 – 20 mg/kgBW daily or 100 – 400 mg daily.

Use in children particularly in malignant condition especially leucemia and abnormalities of certain enzymes, such as Lesch-Nyhan syndrome.

Patients with renal impairment :

The number and interval of administration should be reduced adjusted to the results of monitoring uric acid levels in serum.

For adult patients, use following doses :

Creatinine clearance Dosage
2 – 10 ml/minute 100 mg daily or  with a longer interval
10 – 20 ml/minute 100 – 200 mg daily
> 20 ml/minute Normal dose

The recommended dosage in patients with dialysis :

Allopurinol and its metabolites are removed by renal dialysis. If dialysis need to be done more often, may considered an alternative dose administration of Allopurinol 300 – 400 mg immediately after dialysis without giving more among intervals of time.



  • Patients who hypersensitive to Allopurinol.
  • The condition of acute gout attacks.



  • If symptoms of redness on the skin or allergic symptoms occurs, discontinue the treatment.
  • Avoid use in patients with renal dysfunction or patients with asymptomatic hyperuricemia.
  • In patients with liver damage, it is advisable to perform liver function tests periodically during the early stages of treatment.
  • Risks and benefits of the use of Allopurinol in pregnant and breastfeeding woman should be considered against the fetus, infant or mother.
  • Allopurinol may cause drowsiness. Use with caution in patients who have to work with full concentration, including driving and use machines.
  • Allopurinol should be taken after meals to reduce gastric irritation.
  • It is recommended to increase fluid administration during the use of Allopurinol to prevent kidney stones.
  • If there is itching, anorexia and weight loss, liver function tests should be performed.



  • Allopurinol may increase the toxicity of Cyclophosphamide and other cytotoxic.
  • Allopurinol may inhibits drug metabolism in the liver, such as Warfarin.
  • Allopurinol may enhance the effect of Azathioprine and Merkaptopurin, so that daily doses of these drugs should be reduced prior to treatment with Allopurinol.
  • Allopurinol may prolong the half-life of Chlorpropamide and increase the risk of hypoglycemia, particularly in patients with impaired renal function.
  • The effects of Allopurinol can be reduced by salicylate groups and uricosuric, such as Probenecid.



  • Symptoms of hypersensitivity such as exfoliative, fever, lymphadenopathy, arthralgia, eosinophilia.
  • Skin reactions : Pruritus, maculopapular.
  • Gastrointestinal disorders : Nausea, diarrhea.
  • Headache, vertigo, drowsiness, eye and taste disorders.
  • Blood disorders : Leukopenia, thrombocytopenia, hemolytic anemia, aplastic anemia.



Allopurinol Tablet 300 mg Box, 10 blisters @ 10 tablets Reg. No. GKL0602319210B1







Manufactured by :


Sidoarjo – Indonesia